BLACK DIAMOND THERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Capital Expenditures Incurred but Not yet Paid of $34.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-11.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2023-08-11
- BLACK DIAMOND THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was $0.00.
- BLACK DIAMOND THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2022-09-30 was $0.00.
- BLACK DIAMOND THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- BLACK DIAMOND THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2021 was $148.00K.
- BLACK DIAMOND THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2019 was $94.00K.
- BLACK DIAMOND THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2018 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2023-06-30 | $34.00K 10-Q · filed 2023-08-11 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $0.00 derived: sum of 3 quarters · filed 2023-08-11 | $0.00 10-K · filed 2023-03-09 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-08-11 | $0.00 10-Q · filed 2022-11-08 | -$68.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | -$68.00K derived: sum of 3 quarters · filed 2023-08-11 | -$1.05M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-11 | -$68.00K derived: sum of 2 quarters · filed 2023-03-09 | -$1.05M derived: sum of 3 quarters · filed 2023-03-09 | -$237.00K derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-12-31 | -$68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$1.05M derived: sum of 2 quarters · filed 2023-03-09 | -$237.00K derived: sum of 3 quarters · filed 2023-03-09 | $148.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | -$983.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$169.00K derived: sum of 2 quarters · filed 2022-11-08 | $216.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $814.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.20M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $385.00K 10-Q · filed 2022-05-11 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $0.00 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $94.00K 10-K · filed 2020-03-24 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |